Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06569680 · ClinicalTrials.gov registry record · Phase 2
Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma
A Phase 2 study of Extranodal Marginal Zone Lymphoma, sponsored by Izidore Lossos, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT06569680 is a Phase 2 study of Extranodal Marginal Zone Lymphoma that is actively recruiting participants, run by Izidore Lossos, MD. The registered enrollment target is 35 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06569680, a Phase 2 study of Extranodal Marginal Zone Lymphoma, is actively recruiting participants, sponsored by Izidore Lossos, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test a new medication called Mosunetuzumab to see if it can help people with Extranodal Marginal Zone Lymphoma (EMZL). This study will include people who have not yet received any treatment for cancer and whose cancer is in stage I-IV. This study will help doctors understand if Mosunetuzumab improves outcomes in people with EMZL and if it is safe to use.
Conditions Studied
Interventions
- DRUG Mosunetuzumab
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2024-11-19 |
| Est. Completion | 2030-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06569680
The ClinicalTrials.gov registry entry for NCT06569680 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Izidore Lossos, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Extranodal Marginal Zone Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Mosunetuzumab is the first listed.
NCT06569680 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06569680 about?
NCT06569680 is a clinical study titled "Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma". The purpose of this study is to test a new medication called Mosunetuzumab to see if it can help people with Extranodal Marginal Zone Lymphoma (EMZL). This study will include people who have not yet received any treatment for cancer and whose cancer is in stage I-IV. This study will help doctors und...
What is the current status of trial NCT06569680?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2024-11-19. Estimated completion is 2030-12-01.
What conditions does trial NCT06569680 study?
This clinical trial studies the following conditions: Extranodal Marginal Zone Lymphoma.
What interventions are being tested in trial NCT06569680?
The interventions under investigation include: Mosunetuzumab (DRUG).
Who is sponsoring clinical trial NCT06569680?
This trial is sponsored by Izidore Lossos, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06569680 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.